GSK Will Discuss COX-2 Trial Requirements With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline will meet with FDA to discuss clinical trial requirements for its Phase II dual acting COX-2 inhibitor 406381
You may also be interested in...
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
GSK Committed To Phase II COX-2 Inhibitor Regardless Of FDA Cmte. Outcome
GlaxoSmithKline will continue development of its Phase II COX-2 inhibitor regardless of the outcome of an FDA advisory committee meeting on the safety of the class, CEO J.P. Garnier told investors
GSK COX-2 Data Show No Short-Term Cardiovascular Risk, Company Says
Phase II agent has a safety profile similar to that of Celebrex but offers an “incremental” efficacy benefit over Pfizer’s drug, GSK says. NDA filing is tentatively scheduled for late 2006, but timing may depend on outcome of the Feb. 16-17 FDA advisory committee meeting on COX-2 safety issues.